Get the Daily Brief

All action, no filler. BioBriefs delivers the industry’s 10 must-know updates, every morning.

Latest Biotech News

Base editors sharpen precision — new profiling and engineered ABEs

January 03, 2026

Nature Biotechnology‑published methods expanded base‑editing safety and targeting precision. One paper introduces CHANGE‑seq‑BE, a genome‑wide assay that sensitively maps base editor off‑target...

Combinatorial antifungal micelles show potent, low‑toxicity therapy

January 03, 2026

Two studies report micelle‑based delivery systems that enhance antifungal efficacy while lowering toxicity. Nature Biotechnology published a report on host‑defense peptide mimic micelles that...

Venetoclax resistance tackled: palbociclib combo restores AML sensitivity

January 03, 2026

Oregon Health & Science University researchers reported that combining the BCL2 inhibitor venetoclax with CDK4/6 inhibitor palbociclib produced stronger and more durable anti‑leukemia activity...

Inherited variant reduces clonal hematopoiesis and leukemia risk

January 03, 2026

A GWAS meta‑analysis of more than 640,000 individuals identified a rare noncoding variant, rs17834140‑T, that lowers risk of clonal hematopoiesis of indeterminate potential (CHIP) and subsequent...

Adenine base editors tightened: precision gains cut bystander edits

January 03, 2026

Researchers reported directed-evolution and guide-RNA engineering strategies that materially improved the precision of adenine base editors, reducing unwanted bystander edits and widening the...

Single‑strand deaminase platform rewrites RNA at scale

January 03, 2026

A single‑strand deaminase‑assisted RNA editing platform was published in Nature Biotechnology, describing a system that can simultaneously rewrite multiple bases within single RNA transcripts. The...

Self‑assembling peptide micelles enable combinatorial antifungal therapy

January 03, 2026

Nature Biotechnology published a study demonstrating that a host‑defense peptide mimic self‑assembles into delivery micelles that codeliver antifungals, producing potent combinatorial activity...

AI model predicts small‑molecule–RNA binding without 3D structures

January 03, 2026

SMRTnet, a deep‑learning framework integrating language models with graph attention networks, predicts small‑molecule–RNA interactions using RNA secondary structure rather than tertiary models....

Inherited variant slows clonal hematopoiesis — lowers leukemia risk

January 03, 2026

A large GWAS meta‑analysis spanning more than 640,000 individuals identified a rare noncoding variant, rs17834140‑T, that reduces clonal hematopoiesis of indeterminate potential (CHIP) and...

Venetoclax resistance met by palbociclib combo in AML models

January 03, 2026

Oregon Health & Science University researchers reported that combining venetoclax with the CDK4/6 inhibitor palbociclib produced stronger and more durable anti‑leukemia responses than venetoclax...

AbbVie pays $1.1B for ex‑China rights to Zelgen’s DLL3 trispecific

January 03, 2026

AbbVie signed a licensing deal giving it ex‑China rights to Zelgen Biopharmaceuticals’ trispecific T‑cell engager alveltamig (ZG‑006), paying $100 million up front with up to $1.075 billion in...

Transcenta licenses continuous biomanufacturing to EirGenix

January 03, 2026

Transcenta Therapeutics granted EirGenix a non‑exclusive license to its highly intensified continuous bioprocessing (HiCB) platform, including continuous perfusion and hybrid continuous...

Ultragenyx to slash costs after late‑stage brittle‑bone failures

January 03, 2026

Ultragenyx disclosed failure of two phase‑3 trials in brittle‑bone disease and announced plans for major cost reductions. The company said interim analyses did not meet efficacy thresholds and...

NIH leadership churn deepens — neuro director exits amid instability

January 03, 2026

The NIH continues to lose senior leadership as National Institute of Neurological Disorders and Stroke (NINDS) director Walter Koroshetz, M.D., departs, leaving many institutes under interim...

Antifungal micelles enable combinatorial therapy: potent, lower toxicity

January 03, 2026

Researchers published a Nature Biotechnology paper reporting a self-assembling peptide micelle that codelivers an antifungal drug and a host‑defense peptide mimic to achieve combinatorial...

Single‑strand deaminase assists multiplex RNA edits: new editing platform

January 03, 2026

A Nature Biotechnology study details a single‑strand deaminase‑assisted RNA editing platform that rewrites multiple bases within single RNA transcripts. The authors present a modular system that...

CHANGE‑seq‑BE maps base‑editor off‑targets: unbiased genome‑wide profiling

January 03, 2026

Researchers published CHANGE‑seq‑BE in Nature Biotechnology, a tailored genome‑wide assay that sensitively and unbiasedly profiles off‑target activity induced by base editors. The method...

Directed evolution tightens adenine base editors – fewer bystanders

January 03, 2026

A Nature Biotechnology report shows a directed‑evolution campaign combined with extended guide RNAs produced adenine base editors with markedly improved precision and reduced bystander edits. The...

Palbociclib restores venetoclax sensitivity in AML: preclinical combo breakthrough

January 03, 2026

An Oregon Health & Science University team reported in Cell Reports Medicine that pairing venetoclax with the CDK4/6 inhibitor palbociclib produced stronger and more durable anti‑leukemia activity...

Rare regulatory variant slows clonal hematopoiesis: lowers leukemia risk

January 03, 2026

A Science paper from Vijay G. Sankaran’s lab reports a noncoding regulatory variant, rs17834140‑T, that weakens MSI2 activity and substantially lowers the risk of clonal hematopoiesis of...